New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”
New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit
A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit.
Narrow House GOP Victory Should Point Toward Policy Development Agenda
Two years ago, in the aftermath of the 2020 Congressional election, I wrote: Democrats will retain the majority and the Speaker of the House—second in line to the presidency—will again be Nancy Pelosi.
Don’t Let Pandemic Fatigue Inhibit Pandemic Preparedness
Almost three years after COVID-19 changed the world, pandemic fatigue is in full swing.
American Renewal: A Simpler, More Responsible, and Pro-Growth Tax System
In 2017, lawmakers passed the Tax Cuts and Jobs Act (TCJA), the most significant overhaul of US tax law since 1986.
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
